Published in Drug Week, June 24th, 2005
The U.S. Food and Drug Administration is currently reviewing a new drug application for dapoxetine, developed by Johnson & Johnson, which if approved, would be the first prescription product indicated for the treatment of PE.
According to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.